Poly MedicureQ1 FY27
Poly Medicure Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹1,732P/E: 54.5Market Cap: ₹17.4K CrSector: Healthcare Equipment & Supplies
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- →The company aims to double its revenue by 2030, implying an 18% compounded annual growth over four years, with about 80% organic and 20% inorganic growth.
- →Domestic business is expected to grow over 20%, and international business over 15% for FY27.
- →Europe and Southeast Asia markets are key growth drivers currently, with Europe showing 17%+ growth in Q1.
- →Middle East orders are strong but delayed due to logistics; growth expected once regional situation improves.
- →Approximately 25 new products are in the pipeline for CE marking, expected to launch in the next 3-4 months, augmenting export growth.
- →Renal segment faced a slight de-growth (~3% in Q1) due to competition and pricing pressures but anticipates recovery post government antidumping actions.
- →Acquired companies (PendraCare and Citieffe) expected to grow in mid to high single digits, aiming for mid-teen growth with synergies over time.
- →Overall inorganic growth expected at 3%-4%, organic around 14%-15%.
Margin guidance
Category 3- →Poly Medicure aims to double revenue by FY2030 with a CAGR of about 18%, comprising approximately 14-15% organic growth and 3-4% from acquisitions.
- →Stand-alone revenue guidance for FY27 is INR1,900-2,000 crores with domestic growth over 20% and international growth over 15%.
- →Stand-alone EBITDA margin expected between 25% to 27%, with consolidation margins slightly lower (23%-25%) due to acquisition integration.
- →Q1 EBITDA margin was at 28%, slightly above guidance, helped by price hikes and inventory adjustments.
- →Operating leverage is present but mixed with fixed and variable employee costs; no definitive long-term percentage given.
- →Export growth drivers include Europe (17% organic growth in Q1) and Southeast Asia; Middle East expected to revive once logistical issues resolve.
- →New product pipeline includes approx. 25 CE-marked products coming in next 3-4 months to contribute to growth.
- →Challenges: Renal segment affected by Chinese dumping, but antidumping measures may improve outlook.
- →Capex of INR200-225 crores planned in FY27 to support growth and manufacturing expansion.
3 more insights locked — sign up free to unlock
Fundraise plans
- No explicit mention of any current or future fundraising through debt or equity on page 15 or surrounding pages.
- The company maintains strong liquidity with cash reserves of around INR 850 crores allocated for strategic initiatives.
- Working capital debt exists (~INR 250 crores revolving credit), but no mention of raising additional long-term debt.
- Any inorganic growth or acquisitions will be funded from existing cash reserves, not additional fundraising.
- Capex of INR 200-225 crores planned for FY27, funded likely from internal accruals/cash.
- Management focuses on organic growth and selective acquisitions funded through available resources.
- No stated plans for raising fresh equity or long-term debt in the near term.
In summary, Poly Medicure Limited currently plans to fund growth and capex through internal cash and reserves, without announced intentions for new debt or equity fundraising.
Order book
Yes- →The Middle East order book is described as "pretty strong," indicating robust demand.
- →However, there is a current inability to ship products to the Middle East due to logistics and infrastructure bottlenecks related to the ongoing West Asia crisis.
- →Orders are piling up at ports or in factories because of disrupted shipping schedules, especially container shortages for Middle East ports.
- →Demand from customers remains intact despite these shipping and logistical challenges.
- →There is optimism that once the geopolitical and logistical situation improves, normalcy will return, and the backlog of orders will be fulfilled.
Capex plans
Yes- →Board has allocated funds for expansion both organic and inorganic, including the recent acquisition in Brazil to expand direct sales presence.
- →Focus on technologies around three critical businesses: cardiology, oncology, and orthopedics, and adjacent technologies.
- →Capex planned at two plants under construction: one in Faridabad and one in Noida for medical devices.
- →Expected capex spend for FY27 is between INR 200 crores to INR 225 crores.
- →Manufacturing process shifts from acquired companies (PendraCare and Citieffe) to India are underway but subject to regulatory approvals.
- →Strategic funds of about INR 850 crores in cash reserved for these growth initiatives and acquisitions.
How does Poly Medicure rank vs peers in Healthcare Equipment & Supplies?
Pro feature1Poly Medicure
Rev 3Mar 3
See full Healthcare Equipment & Supplies sector rankings
How does Poly Medicure rank in Healthcare Equipment & Supplies?
Compare Poly Medicure against every Healthcare Equipment & Supplies company (Q1 FY27) on revenue, margins and earnings-call signals.